Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

RAL vs ECG: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ECG Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

ECG Overall Winner 6-Pillar Tally: RAL 3 – 3 ECG Matrix Metrics: RAL 4 – 6 ECG

As of Nov 17, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over Ralliant Corporation (RAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RAL carries a Unified Composite Score of 35.6/100 (SELL) at $67.14 (18.6x Forward P/E, 15.0% operating margin), whereas ECG carries 50.8/100 (HOLD) at $84.73 (11.7x Forward P/E, 8.2% operating margin).

  • Technical & Structure Timing Caution: RAL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile ECG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RAL vs ECG
RAL NYSE
Ralliant Corporation
Industrial Instruments For Measurement, Display, And Control
$67.14
-0.79% 1D
Market Cap $7.6B
TTM Revenue $2.28B
Forward P/E 18.6x
Beta / 30D Vol 1.60β · 67% Vol
Unified Composite Score
35.6 / 100 SELL
Tech 20.0 Fund 43.0 Flow 50.0 Mom 68.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $68.59 · SMA50: $69.11
ECG NYSE Head-to-Head Winner
Everus Construction Group, Inc.
Operative Builders
$84.73
+2.18% 1D
Market Cap $4.4B
TTM Revenue $4.66B
Forward P/E 11.7x
Beta / 30D Vol 2.16β · 127% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 60.0 Fund 58.0 Flow 54.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.6%), weak momentum, RSI 40
RSI-14: 40.1 · SMA20: $92.92 · SMA50: $107.29

6-Pillar Scorecard Institutional Category Breakdown (RAL 3 – 3 ECG)

Columns: Metric · RAL · ECG
1. Valuation Multiples ECG
Forward P/E 18.6x 11.7x
Trailing P/E 21.3x 15.1x
PEG Ratio N/M N/M
EV / Revenue 3.3x 1.0x
2. Growth & Scale ECG
Revenue Growth (YoY) +17.2% +40.3%
Earnings Growth (YoY) +120.0% +61.3%
TTM Revenue (USD) $2.28B $4.66B
Market Cap $7.6B $4.4B
3. Profitability & Quality RAL
Gross Margin 51.6% 13.6%
Operating Margin 15.0% 8.2%
Net Profit Margin -52.1% 6.2%
Return on Equity (ROE) -51.8% 40.3%
4. Balance Sheet & Cash Flow RAL
Cash Generation (TTM) $460M EBITDA $237M
Cash Flow Margin 20.2% EBITDA Mgn 5.1%
Net Cash / Leverage $14.59 Book/Sh · -51.8% ROE $439M Net Debt (0.81x D/E)
Dividend Yield 0.28% None (0.00%)
5. Options & Positioning ECG
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 41.7% (58th %ile) 93.7% (12th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Markdown
6. R&D & Supply-Chain Moat RAL
OpEx & R&D Intensity 36.6% of Rev ($833M) 5.4% of Rev ($252M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Electronic Components Operator Engineering & Construction Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RAL (4) vs ECG (6)
Institutional Metric RAL ECG Criterion Row Edge
Market Capitalization
Scale
$7.6B $4.4B Larger Scale RAL
Trailing P/E Ratio
Valuation
21.3x 15.1x Lower Multiple ECG
Forward P/E Ratio
Valuation
18.6x 11.7x Lower Multiple ECG
Revenue Growth (YoY)
Growth
+17.2% +40.3% Higher Growth ECG
Operating Margin (TTM)
Profitability
15.0% 8.2% Higher Margin RAL
Net Profit Margin
Profitability
-52.1% 6.2% Higher Margin ECG
Return on Equity (ROE)
Capital Efficiency
-51.8% 40.3% Higher ROE ECG
52-Week Range Position
Momentum
78% ($37–$75) 14% ($70–$172) Stronger Trend RAL
Beta / 30D Volatility
Risk Regime
1.60β · 67% Vol 2.16β · 127% Vol Lower Realized Risk RAL
Unified Institutional Score
Composite Signal
35.6 / 100 (SELL) 50.8 / 100 (HOLD) Higher Composite ECG
Trailing 12M Revenue (USD)
Operating Scale
$2.28B $4.66B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
51.6% 13.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.3x EV/Rev N/M PEG · 1.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$460M EBITDA ($14.59 Book/Sh · -51.8% ROE) $237M ($439M Net Debt (0.81x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAL +21.85 pp
RAL: -0.2% · ECG: -22.05%
3M Horizon RAL +35.55 pp
RAL: +0.95% · ECG: -34.6%
6M Horizon RAL +56.65 pp
RAL: +14.58% · ECG: -42.07%
1Y Horizon RAL +47.52 pp
RAL: +41.48% · ECG: -6.04%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on RAL vs ECG. Trailing 12-month operating profitability (RAL 15.0% vs ECG 8.2%) and valuation multiples (RAL 18.6x vs ECG 11.7x Forward P/E) are benchmarked directly in Pillar 4 below.

RAL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.28B
Gross Margin51.6%
Op. Margin15.0%
ROE / Fwd P/E-51.8% · 18.6x
ECG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.66B
Gross Margin13.6%
Op. Margin8.2%
ROE / Fwd P/E40.3% · 11.7x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RAL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 41.7%
IV Percentile 58th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ECG BREAKDOWN
135d in phase · OBV ACCUMULATION
Current IV 93.7%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact ECG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RAL Moat Profile Scale & Operating Efficiency Moat
Electronic Components Operator
Competes within the Electronic Components value chain with $7.6B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 36.6% of Rev ($833M)
90D Engineering Disclosures 0 Published
ECG Moat Profile High-Margin Pricing Power Moat
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $4.4B market capitalization and 8.2% operating margin.
OpEx & R&D Reinvestment 5.4% of Rev ($252M)
90D Engineering Disclosures 0 Published

Investor FAQ RAL vs ECG Key Questions & Quantitative Answers

As of Nov 17, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over Ralliant Corporation (RAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). RAL carries a Unified Composite Score of 35.6/100 (SELL) at $67.14 (18.6x Forward P/E, 15.0% operating margin), whereas ECG carries 50.8/100 (HOLD) at $84.73 (11.7x Forward P/E, 8.2% operating margin). Technical & Structure Timing Caution: RAL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3); meanwhile ECG is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECG leads the Growth & Scale pillar: RAL posts +17.2% YoY revenue growth and +120.0% YoY earnings growth on $2.28B TTM revenue (51.6% gross margin, 15.0% operating margin), compared with ECG at +40.3% YoY revenue growth and +61.3% YoY earnings growth on $4.66B TTM revenue (13.6% gross margin, 8.2% operating margin). On trailing 12-month operating scale, RAL generates $2.28B in USD-normalized revenue versus $4.66B for ECG. In operating R&D and SG&A reinvestment, RAL deploys 36.6% of Rev ($833M) (0 90-day corporate R&D disclosures) versus 5.4% of Rev ($252M) (0 disclosures) for ECG.

ECG screens cheaper on headline valuation multiples. RAL trades at 18.6x Forward P/E, 21.3x Trailing P/E, N/M PEG, and 3.3x EV/Revenue (20.2% EBITDA margin), whereas ECG trades at 11.7x Forward P/E, 15.1x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (5.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RAL (-51.8% ROE) versus ECG (40.3% ROE) capital efficiency.

In options market volatility and institutional positioning, RAL carries 41.7% implied volatility (58th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.60β · 67% Vol realized risk). By comparison, ECG carries 93.7% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.16β · 127% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.